MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...

ULSCs is under clinical development by RESTEM and currently in Phase I for Polymyositis. According to GlobalData, Phase I drugs for Polymyositis does not have sufficient historical data to build an ...

Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.